摘要
肿瘤基础研究和基因分子生物学技术的进步促进了伴随诊断和相关抗肿瘤药物的发展。目前伴随诊断应用的最大分支是通过伴随诊断获得患者针对特定治疗药物的治疗反应的信息,协助制定治疗方案,实现患者的个体化治疗。但伴随诊断及其相关药物在研发和应用上与传统药物有较大不同,本文试对其做一综述。
Companion diagnostics（CDx） and CDx related antitumor drugs develope very fast recently for the improvement of basic research of oncomolecular biology. Antitumor drugs is the largest branch of CDx nowadays. Doctors may prognosis drug effect by CDx, which is important in making treatment plan and individualized treatment. There are many differences between traditional chemotherapy drugs and CDx related drugs. Here is a review of companion diagnostics related antitumor drugs.
作者
张俊琦
周斌
ZHANG Junqi1, ZHOU Bin2(1.Pharmacy Department, Children ＇s Hospital, Fudan University, Shanghai 201102, China, 2. Vascular Surgery Department, East Hospital, Tongji University School of Medicine, Shanghai 200120, Chin)
出处
《中国现代应用药学》
CAS
CSCD
北大核心
2018年第3期454-459,共6页
Chinese Journal of Modern Applied Pharmacy
关键词
伴随诊断
抗肿瘤药物
发展现状
companion diagnostics
antitumor drugs
progress
